Endocrine Abstracts

Somatostatin analogues (SSA) are used to treat different forms of hyperinsulinemic hypoglycemia (HH) in children and adults and therapeutic effect is achieved by suppressing insulin secretion from pancreatic β-cells by complex mechanisms. These treatments might be associated with several side effects, can even cause the worsening of severity of hypoglycemia. This is a report of the treatment of HH with SSA in patient with Activating Mutation (GCK), c.295T>C (p.Trp99Ar...

Introduction: Clinical manifestation of hypophysitis depends on presence of hormonal abnormalities and/or enlargement of pituitary structures. Both the diagnosis and treatment still remain challenging. Hormonal replacement is the basic therapy, while steroids are the first-line treatment in case of mass related symptoms. The course of the disease varies from spontaneous remission to atrophy of the pituitary gland.Aim: To characterize and sum up clinical/...

Introduction: Diagnostic delay remains significant among the patients with acromegaly, even though the disease awareness has improved over the years.Aim: The aim was to investigate the diagnostic delay and symptoms present at diagnosis of acromegaly among the newly-diagnosed patients.Material and methods: 72 consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were evaluated. Division into groups based on: gen...

Silent corticotroph pituitary neuroendocrine tumours (PiTNETs) are a subtype of nonfunctioning PiTNETs, that present positive immunostaining for adrenocorticotropin (ACTH) and/or show the expression of the transcription factor T-PIT without clinical signs of hypercortisolemia. They constitute 20% of all corticotroph PitNETs and manifest in most cases as macroadenoma with suprasellar extension and a higher tendency to apoplexy. We present a 33-year-old male with aggressive cour...

Introduction: The group of young adults with acromegaly, despite initial reports about their aggressive course of disease, has not been thoroughly characterized. Aim: Our aim was to investigate the differences between the patients with early-onset acromegaly and with onset in older age. Material and methods: Consecutive patients diagnosed with acromegaly between 01.2014 and 12.2021 were included in this retrospective study, approve...

Giant prolactinomas are very rare and constitute 2-3% of all lactotroph PitNETs with male preponderance. We present a case series of five male patients with giant prolactinomas with various clinical presentation. Case 1: A 66-year-old male hospitalized due to left peripheral facial palsy. In computer tomography (CT) pituitary mass (41 x 43 x 64 mm) invading cavernous/sphenoid sinuses/carotid arteries/optic chiasm was visualized. Bitemporal hemianopia/hea...

Osilodrostat as an inhibitor of adrenal 11B-hydroxylas, is an effective medication used in the management of endogenous hypercortisolism. There are limited data regarding usage of osilodrostat in ectopic Cushing Syndrome (CS). Surgery is usually the first line treatment in ectopic CS, however the source of ectopic hormonal production often remains undiscovered for a long period of time. Meanwhile dangerous state of severe hypercortisolism needs to be managed pharmacologically ...

Somatostatin analogues (SSA) are first/second line treatment in the management of acromegaly and Cushing disease (CD), however, recent data suggest that they can be effective in the management of non-functioning pituitary neuroendocrine tumour (PitNET). We present one clinically silent gonadotroph PitNET treated with octreotide and two silent corticotroph PitNETs treated with pasireotide.Case 1: A 50-year-old female presented with frontal headache and vi...

Introduction: Combined pituitary hormone deficiency (CPHD) due to PROP1 mutation is a rare cause of childhood-onset pituitary disfunction. Treatment with growth hormone is crucial for the proper development during childhood and adolescence, and to maintain adequate metabolic processes in the adulthood. There are other factors influencing patients metabolism e.g. steroid and estradiol/testosterone treatment.Aim: To assess metabolic status of patients with...

Introduction: The time, degree and mode of pituitary function deterioration in patients with PROP1 mutation is not fully known and understood.Aim: To investigate the time and mode of pituitary function deterioration in the families/sporadic patients with PROP1 mutation during longitudinal observation.Methods: We performed a retrospective longitudinal (33 years, SD=12) analysis of 22 patients (11M/11W) with PROP1 mutation, including...